Non-exclusive drug discount agreement for Beclometason/Formoterol (ATC R03AK08)
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Beclometason/Formoterol (ATC-Code nach WHO: R03AK08)
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
The actual demand is unknown and depends on numerous factors. No minimum order quantities are guaranteed, leading to po...
The buyer reserves the right to terminate the open-house procedure early if exclusive agreements are concluded. In such...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- May 31, 2027
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until May 2027
- Agreement to provide Beclometason/Formoterol drugs (except 100µg/6µg aerosol) at a discounted price based on the negotiated discount terms.
- Supply to AOK PLUS insured members in Saxony and Thuringia.
Show full summary
This notice is for a non-exclusive drug discount agreement (Rabattvereinbarung) under §130a Abs.8 SGB V for the active ingredient Beclometason/Formoterol (ATC R03AK08), excluding the 100µg/6µg dosage aerosol. It is an open-house model open to all qualified pharmaceutical companies. No estimated value or guaranteed volume is provided. The agreement ends by 31 May 2027.
Risks
The actual demand is unknown and depends on numerous factors. No minimum order quantities are guaranteed, leading to po...
The buyer reserves the right to terminate the open-house procedure early if exclusive agreements are concluded. In such...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as defined in §4 Abs.18 AMG.
Administrative
- Must submit participation documents via the DTVP portal (electronic submission required, but not via the standard bidder tool due to open-house nature).
- Must maintain absolute confidentiality of the participation documents and discount agreement terms.
Requirements may be incomplete.
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive drug discount agreement for Beclometason/Formoterol (ATC R03AK08)
Open-house model for a non-exclusive discount agreement on Beclometason/Formoterol products (excluding 100µg/6µg aerosol). No guaranteed volume. Agreement ends 31 May 2027.
Location
Duration
Category
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Beclometason/Formoterol (ATC-Code nach WHO: R03AK08)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 12 Mar 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 176734-2026
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
The actual demand is unknown and depends on numerous factors. No minimum order quantities are guaranteed, leading to po...
The buyer reserves the right to terminate the open-house procedure early if exclusive agreements are concluded. In such...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications